Library — CHDR

Search

Filter

Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.

Alvarez-Jimenez R, Groeneveld GJ, van Gerven JM, Goulooze SC, Baakman AC, Hay JL, Stevens J

British journal of clinical pharmacology, 2016 Sep; 82(4):1011-21

View publication
Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects.

Spiegelstein O, Stevens J, Van Gerven J, Nathan PJ, Maynard JP, Mayleben DW, Hellriegel E, Yang R

Journal of psychopharmacology (Oxford, England), 2016 Sep; 30(10):983-93

View publication
Measuring blood-brain barrier penetration using the NeuroCart, a CNS test battery.

Groeneveld GJ, Hay JL, Van Gerven JM

Drug discovery today. Technologies, 2016 Jun

View publication
NS11821, a partial subtype-selective GABAA agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects.

Zuiker RG, Chen X, Østerberg O, Mirza NR, Muglia P, de Kam M, Klaassen ES, van Gerven JM

Journal of psychopharmacology (Oxford, England), 2016 Feb; 30(3):253-62

View publication
First in human study with a prodrug of galantamine: Improved benefit-risk ratio?

Baakman AC, 't Hart E, Kay DG, Stevens J, Klaassen ES, Maelicke A, Groeneveld GJ

Alzheimer's & dementia (New York, N. Y.), 2016 Jan; 2(1):13-22

View publication
The effects of the nonselective benzodiazepine lorazepam and the α2 /α3 subunit-selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levels.

Te Beek ET, Chen X, Jacobs GE, Nahon KJ, de Kam ML, Lappalainen J, Cross AJ, van Gerven JM, Hay JL

Clinical pharmacology in drug development, 2015 Feb; 4(2):149-54

View publication
AZD6280, a novel partial γ-aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers.

Chen X, Jacobs G, de Kam ML, Jaeger J, Lappalainen J, Maruff P, Smith MA, Cross AJ, Cohen A, van Gerven J

Journal of clinical psychopharmacology, 2015 Jan; 35(1):22-33

View publication
The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.

Chen X, Jacobs G, de Kam M, Jaeger J, Lappalainen J, Maruff P, Smith MA, Cross AJ, Cohen A, van Gerven J

British journal of clinical pharmacology, 2014 Nov; 78(6):1298-314

View publication
Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant.

Hoch M, van Gorsel H, van Gerven J, Dingemanse J

Journal of clinical pharmacology, 2014 Aug; 54(9):979-86

View publication

«
1
2
3
4
5
6
7
8
9
10
11
»